610 related articles for article (PubMed ID: 34670043)
1. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.
Sanyal AJ; Van Natta ML; Clark J; Neuschwander-Tetri BA; Diehl A; Dasarathy S; Loomba R; Chalasani N; Kowdley K; Hameed B; Wilson LA; Yates KP; Belt P; Lazo M; Kleiner DE; Behling C; Tonascia J;
N Engl J Med; 2021 Oct; 385(17):1559-1569. PubMed ID: 34670043
[TBL] [Abstract][Full Text] [Related]
2. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
3. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
[TBL] [Abstract][Full Text] [Related]
4. Analysis of a Simulation Model to Estimate Long-term Outcomes in Patients with Nonalcoholic Fatty Liver Disease.
Chhatwal J; Dalgic OO; Chen W; Samur S; Bethea ED; Xiao J; Hur C; Corey KE; Loomba R
JAMA Netw Open; 2022 Sep; 5(9):e2230426. PubMed ID: 36098969
[TBL] [Abstract][Full Text] [Related]
5. Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.
Simon TG; Roelstraete B; Sharma R; Khalili H; Hagström H; Ludvigsson JF
Hepatology; 2021 Nov; 74(5):2410-2423. PubMed ID: 33811766
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
Shelley K; Articolo A; Luthra R; Charlton M
BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
[TBL] [Abstract][Full Text] [Related]
7. Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis.
Huang DQ; Noureddin N; Ajmera V; Amangurbanova M; Bettencourt R; Truong E; Gidener T; Siddiqi H; Majzoub AM; Nayfeh T; Tamaki N; Izumi N; Yoneda M; Nakajima A; Idilman R; Gumussoy M; Oz DK; Erden A; Allen AM; Noureddin M; Loomba R
Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):829-836. PubMed ID: 37419133
[TBL] [Abstract][Full Text] [Related]
8. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
Younossi ZM; Anstee QM; Wai-Sun Wong V; Trauner M; Lawitz EJ; Harrison SA; Camargo M; Kersey K; Subramanian GM; Myers RP; Stepanova M
Gastroenterology; 2021 Apr; 160(5):1608-1619.e13. PubMed ID: 33307033
[TBL] [Abstract][Full Text] [Related]
9. Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients.
Ito T; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hayashi K; Nishimura D; Toyoda H; Kumada T; Goto H; Hirooka Y
J Gastroenterol Hepatol; 2019 Jan; 34(1):207-214. PubMed ID: 30144360
[TBL] [Abstract][Full Text] [Related]
10. The Potential Role of Fatigue in Identifying Patients With NASH and Advanced Fibrosis Who Experience Disease Progression.
Younossi ZM; Stepanova M; Myers RP; Younossi I; Henry L
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):970-977.e1. PubMed ID: 35533993
[TBL] [Abstract][Full Text] [Related]
11. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis.
Mózes FE; Lee JA; Vali Y; Alzoubi O; Staufer K; Trauner M; Paternostro R; Stauber RE; Holleboom AG; van Dijk AM; Mak AL; Boursier J; de Saint Loup M; Shima T; Bugianesi E; Gaia S; Armandi A; Shalimar ; Lupșor-Platon M; Wong VW; Li G; Wong GL; Cobbold J; Karlas T; Wiegand J; Sebastiani G; Tsochatzis E; Liguori A; Yoneda M; Nakajima A; Hagström H; Akbari C; Hirooka M; Chan WK; Mahadeva S; Rajaram R; Zheng MH; George J; Eslam M; Petta S; Pennisi G; Viganò M; Ridolfo S; Aithal GP; Palaniyappan N; Lee DH; Ekstedt M; Nasr P; Cassinotto C; de Lédinghen V; Berzigotti A; Mendoza YP; Noureddin M; Truong E; Fournier-Poizat C; Geier A; Martic M; Tuthill T; Anstee QM; Harrison SA; Bossuyt PM; Pavlides M;
Lancet Gastroenterol Hepatol; 2023 Aug; 8(8):704-713. PubMed ID: 37290471
[TBL] [Abstract][Full Text] [Related]
12. Trends in Characteristics, Mortality, and Other Outcomes of Patients With Newly Diagnosed Cirrhosis.
Orman ES; Roberts A; Ghabril M; Nephew L; Desai AP; Patidar K; Chalasani N
JAMA Netw Open; 2019 Jun; 2(6):e196412. PubMed ID: 31251379
[TBL] [Abstract][Full Text] [Related]
13. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV.
Limketkai BN; Mehta SH; Sutcliffe CG; Higgins YM; Torbenson MS; Brinkley SC; Moore RD; Thomas DL; Sulkowski MS
JAMA; 2012 Jul; 308(4):370-8. PubMed ID: 22820790
[TBL] [Abstract][Full Text] [Related]
14. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Taylor RS; Taylor RJ; Bayliss S; Hagström H; Nasr P; Schattenberg JM; Ishigami M; Toyoda H; Wai-Sun Wong V; Peleg N; Shlomai A; Sebastiani G; Seko Y; Bhala N; Younossi ZM; Anstee QM; McPherson S; Newsome PN
Gastroenterology; 2020 May; 158(6):1611-1625.e12. PubMed ID: 32027911
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of chronic hepatitis C patients related to baseline liver fibrosis stage: a hospital-based linkage study.
Huang Y; de Boer WB; Adams LA; MacQuillan G; Bulsara MK; Jeffrey GP
Intern Med J; 2015 Jan; 45(1):48-54. PubMed ID: 25371273
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease.
Peleg N; Sneh Arbib O; Issachar A; Cohen-Naftaly M; Braun M; Shlomai A
PLoS One; 2018; 13(8):e0202393. PubMed ID: 30106985
[TBL] [Abstract][Full Text] [Related]
17. Patients with stage 3 compared to stage 4 liver fibrosis have lower frequency of and longer time to liver disease complications.
Axley P; Mudumbi S; Sarker S; Kuo YF; Singal AK
PLoS One; 2018; 13(5):e0197117. PubMed ID: 29746540
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study.
Fujii H; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Yamamura S; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Kawada N; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T;
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):370-379. PubMed ID: 35051649
[TBL] [Abstract][Full Text] [Related]
19. Disease State Transition Probabilities Across the Spectrum of NAFLD: A Systematic Review and Meta-Analysis of Paired Biopsy or Imaging Studies.
Le P; Payne JY; Zhang L; Deshpande A; Rothberg MB; Alkhouri N; Herman W; Hernandez AV; Schleicher M; Ye W; Dasarathy S
Clin Gastroenterol Hepatol; 2023 May; 21(5):1154-1168. PubMed ID: 35933075
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population.
Kogiso T; Sagawa T; Kodama K; Taniai M; Hashimoto E; Tokushige K
J Gastroenterol Hepatol; 2020 Sep; 35(9):1579-1589. PubMed ID: 31975453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]